Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
2011 ◽
Vol 12
(8)
◽
pp. 735-742
◽
Keyword(s):
Phase 3
◽
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8005-8005
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):